Mubeena Begum, MD
Internal Medicine · Gulfport, MSNPI 1669624078
Payments from drug & device makers
Across 91 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$201
- AstraZeneca$169
- Amgen$162
- Pfizer$148
- Lilly USA, LLC$108
- Johnson & Johnson$89
- plus $585 from 19 others
What the payments were for
- Food & beverage$1,463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $201 |
| AstraZeneca | 10 | $169 |
| Amgen | 9 | $162 |
| Pfizer | 11 | $148 |
| Lilly USA, LLC | 7 | $108 |
| Johnson & Johnson | 7 | $89 |
| Novartis | 5 | $86 |
| Novo Nordisk | 4 | $71 |
| Astellas Pharma US Inc | 3 | $53 |
| Nestle Healthcare Nutrition Inc. | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| UCB, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Boehringer Ingelheim | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Bayer | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
| PBG Puerto Rico LLC | 1 | $11 |
| GRT US Holding, Inc. | 1 | $10 |
How this compares
$1,463 in reported general payments places this provider in the 70th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $107,896 |
| JardianceEmpagliflozin | 93 | $92,488 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $37,110 |
| MyrbetriqMirabegron | 52 | $30,851 |
| ProliaDenosumab | 15 | $25,917 |
| FarxigaDapagliflozin Propanediol | 30 | $25,525 |
| EliquisApixaban | 27 | $25,363 |
| JanuviaSitagliptin Phosphate | 22 | $23,470 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $21,703 |
| XareltoRivaroxaban | 20 | $20,507 |
| TrulicityDulaglutide | 17 | $19,840 |
| LinzessLinaclotide | 33 | $19,098 |
| MounjaroTirzepatide | 13 | $13,337 |
| EntrestoSacubitril/Valsartan | 12 | $8,595 |
| Repatha SureclickEvolocumab | 13 | $8,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $71 | $107,896107 claims |
| Boehringer IngelheimJardiance | $19 | $92,48893 claims |
| GSKTrelegy Ellipta | $19 | $37,11046 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $108 | $33,17730 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $30,85152 claims |
| AmgenProlia | $162 | $25,91715 claims |
| AstraZenecaFarxiga | $169 | $25,52530 claims |
| PfizerEliquis | $148 | $25,36327 claims |
| Johnson & JohnsonXarelto | $89 | $20,50720 claims |
| AbbVieLinzess | $201 | $19,09833 claims |
| NovartisEntresto | $86 | $8,59512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Gulfport
- David PendleyGulfport$336K
- Mousa MaaloufGulfport$14K
- David LarosaGulfport$14K
- Phillip ComptonGulfport$10K
- Lynn LeatherwoodGulfport$10K
- Jay SegarraGulfport$9K
- Boyd BenefieldGulfport$7K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.